インフルエンザA及びB感染病:治療薬パイプラインレビュー(2014年上半期)

◆英語タイトル:Influenza A And B Infections - Pipeline Review, H1 2014
◆商品コード:GMDHC4916IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年4月30日
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥214,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥642,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Influenza A And B Infections – Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Influenza A And B Infections – Pipeline Review, H1 2014’, provides an overview of the Influenza A And B Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Influenza A And B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A And B Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Influenza A And B Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Influenza A And B Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Influenza A And B Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Influenza A And B Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Influenza A And B Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Influenza A And B Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Influenza A And B Infections Overview 6
Therapeutics Development 7
Pipeline Products for Influenza A And B Infections – Overview 7
Pipeline Products for Influenza A And B Infections – Comparative Analysis 8
Influenza A And B Infections – Therapeutics under Development by Companies 9
Influenza A And B Infections – Therapeutics under Investigation by Universities/Institutes 11
Influenza A And B Infections – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Influenza A And B Infections – Products under Development by Companies 15
Influenza A And B Infections – Products under Investigation by Universities/Institutes 16
Influenza A And B Infections – Companies Involved in Therapeutics Development 17
Toyama Chemical Co., Ltd. 17
Crucell N.V. 18
Cocrystal Discovery, Inc. 19
Beech Tree Labs, I;nc. 20
MI.TO. Technology S.r.L. 21
Influenza A And B Infections – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 28
Drug Profiles 30
favipiravir – Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
BTL-TML001 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CR-9114 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules For Influenza – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza A and B Virus Infection – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecules For Influenza Virus Infection – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Influenza A And B Infections – Recent Pipeline Updates 37
Influenza A And B Infections – Dormant Projects 39
Influenza A And B Infections – Product Development Milestones 40
Featured News & Press Releases 40
Dec 20, 2013: Biota Reports That Laninamivir Octanoate is Approved for the Prevention of Influenza in Japan 40
Dec 05, 2013: Biota Initiates Dosing in Phase 2 IGLOO Trial of LANI in the Northern Hemisphere 40
Aug 05, 2013: FDA approves supply of GSK’s quadrivalent influenza vaccine in US 40
Jun 11, 2013: Biota Initiates Phase II Trial Of Laninamivir Octanoate For Treatment Of Influenza In Adults 41
Jun 10, 2013: Sanofi’s New Four-Strain Influenza Vaccine Fluzone Receives FDA Approval For Broad Age Range Of Children And Adults 41
Apr 11, 2013: Sanofi Pasteur Announces Acceptance Of Marketing Authorization Application For Quadrivalent Formulation Of Vaxigrip In Europe 41
Apr 03, 2013: GSK’s Four-strain Seasonal Influenza Vaccine Receives Marketing Authorization In Germany And UK 42
Apr 01, 2013: BioCryst Pharma Receives Preliminary Comment Letter From FDA For Peramivir 43
Feb 06, 2013: FluGen Presents Data On Universal Flu Vaccine Redee Flu At World Health Organization Influenza Meeting 44
Dec 17, 2012: GSK’s Seasonal Influenza Vaccine Fluarix Quadrivalent Obtains FDA Approval 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
Number of Products under Development for Influenza A And B Infections, H1 2014 7
Number of Products under Development for Influenza A And B Infections - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Late Stage Development, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Influenza A And B Infections - Pipeline by Toyama Chemical Co., Ltd., H1 2014 17
Influenza A And B Infections - Pipeline by Crucell N.V., H1 2014 18
Influenza A And B Infections - Pipeline by Cocrystal Discovery, Inc., H1 2014 19
Influenza A And B Infections - Pipeline by Beech Tree Labs, Inc., H1 2014 20
Influenza A And B Infections - Pipeline by MI.TO. Technology S.r.L., H1 2014 21
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Stage and Target, H1 2014 24
Number of Products by Stage and Mechanism of Action, H1 2014 26
Number of Products by Stage and Route of Administration, H1 2014 27
Number of Products by Stage and Molecule Type, H1 2014 29
Influenza A And B Infections Therapeutics - Recent Pipeline Updates, H1 2014 37
Influenza A And B Infections - Dormant Projects, H1 2014 39

List of Figures
Number of Products under Development for Influenza A And B Infections, H1 2014 7
Number of Products under Development for Influenza A And B Infections - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Top 10 Target, H1 2014 23
Number of Products by Stage and Top 10 Target, H1 2014 24
Number of Products by Top 10 Mechanism of Action, H1 2014 25
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 26
Number of Products by Stage and Top 10 Route of Administration, H1 2014 27
Number of Products by Top 10 Molecule Type, H1 2014 28
Number of Products by Stage and Top 10 Molecule Type, H1 2014 29

【掲載企業】

Toyama Chemical Co., Ltd.
Crucell N.V.
Cocrystal Discovery, Inc.
Beech Tree Labs, I;nc.
MI.TO. Technology S.r.L.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[インフルエンザA及びB感染病:治療薬パイプラインレビュー(2014年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆